Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherGastrointestinal, Hepatic, Pulmonary, and Renal

Neutralizing MIP3a reduces renal immune cell infiltration and progressive renal injury in young obese Dahl salt-sensitive rats

Ubong S Ekperikpe, Bibek Poudel, Corbin A Shields, Sautan Mandal, Denise C Cornelius and Jan M Williams
Journal of Pharmacology and Experimental Therapeutics December 5, 2022, JPET-AR-2022-001298; DOI: https://doi.org/10.1124/jpet.122.001298
Ubong S Ekperikpe
1Pharmacology and Toxicology, University of Mississippi Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ubong S Ekperikpe
Bibek Poudel
2University of Mississippi Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corbin A Shields
2University of Mississippi Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sautan Mandal
2University of Mississippi Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise C Cornelius
2University of Mississippi Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan M Williams
2University of Mississippi Medical Center, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jmwilliams5@umc.edu
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Recently, we reported that the early progression of renal injury in obese Dahl salt-sensitive leptin receptor mutant (SSLepRmutant) rats was associated with increased macrophage inflammatory protein alpha (MIP3a) expression prior to puberty. Therefore, this study tested the hypothesis that MIP3α plays a role in recruiting immune cells, thereby triggering renal inflammation and early progressive renal injury in SSLepRmutant rats prior to puberty. Four-week-old SS and SSLepRmutant rats either served as control (IgG; i.p., every other day) or received MIP3a neutralizing antibody (MNA; 100 µg/kg) for 4 weeks. MNA reduced circulating and renal MIP3a levels and pro-inflammatory immune cells by 50%. While MNA treatment did not affect blood glucose and plasma cholesterol levels, MNA markedly decreased insulin resistance and triglyceride levels in SSLepRmutant rats. We observed no differences in MAP between SS and SSLepRmutant rats, and MNA had no effect on MAP in either strain. Proteinuria was significantly increased in SSLepRmutant rats versus SS rats over the course of the study. Treatment with MNA markedly decreased proteinuria in SSLepRmutant rats while not affecting SS rats. Also, MNA decreased glomerular and tubular injury and renal fibrosis in SSLepRmutant rats while not affecting SS rats. Overall, these data indicate MIP3a plays an important role in renal inflammation during the early progression of renal injury in obese SSLepRmutant rats prior to puberty. These data also suggest that MIP3a may be a novel therapeutic target to inhibit insulin resistance and prevent progressive proteinuria in obese children.

Significance Statement Childhood obesity is increasing at an alarming rate and is now being associated with renal disease. While most studies have focused on the mechanisms of renal injury associated with adult obesity, few studies have examined the mechanisms of renal injury involved during childhood obesity. In the current study, we observed that the progression of renal injury in obese SSLepRmutant rats was associated with an increase in MIP3a, a chemokine, before puberty, and inhibition of MIP3a markedly reduced renal injury.

  • chemokines
  • inflammation
  • kidney disease
  • obesity
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 384 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 384, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Neutralizing MIP3a reduces renal immune cell infiltration and progressive renal injury in young obese Dahl salt-sensitive rats
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherGastrointestinal, Hepatic, Pulmonary, and Renal

MIP3a in Progressive Renal Injury Associated With Obesity

Ubong S Ekperikpe, Bibek Poudel, Corbin A Shields, Sautan Mandal, Denise C Cornelius and Jan M Williams
Journal of Pharmacology and Experimental Therapeutics December 5, 2022, JPET-AR-2022-001298; DOI: https://doi.org/10.1124/jpet.122.001298

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherGastrointestinal, Hepatic, Pulmonary, and Renal

MIP3a in Progressive Renal Injury Associated With Obesity

Ubong S Ekperikpe, Bibek Poudel, Corbin A Shields, Sautan Mandal, Denise C Cornelius and Jan M Williams
Journal of Pharmacology and Experimental Therapeutics December 5, 2022, JPET-AR-2022-001298; DOI: https://doi.org/10.1124/jpet.122.001298
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A Novel Long-Acting GLP-2, HM15912, for Short Bowel Syndrome
  • H2S Overproduction and Colonic Hypomotility in DM
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics